 |
 Video: What is a Stock Split?
|
|
|
| Adaptive Biotechnologies is a commercial-stage company developing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s clinical diagnostic product, clonoSEQ, is authorized for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. Using its collaboration with Microsoft Corporation, Co. is creating a map of the interaction between the immune system and disease. According to our ADPT split history records, Adaptive Biotechnologies has had 3 splits. | |
|
Adaptive Biotechnologies (ADPT) has 3 splits in our ADPT split history database. The first split for ADPT took place on April 06, 1992. This was a 2 for 1
split, meaning for each share of ADPT owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. ADPT's second split took place on January 31, 1994. This was a 2 for 1
split, meaning for each share of ADPT owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split. ADPT's third split took place on November 18, 1996. This was a 2 for 1
split, meaning for each share of ADPT owned pre-split, the shareholder now owned 2 shares. For example, a 4000 share position pre-split, became a 8000 share position following the split.
When a company such as Adaptive Biotechnologies splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the ADPT split history from start to finish, an original position size of 1000 shares would have turned into 8000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adaptive Biotechnologies shares, starting with a $10,000 purchase of ADPT, presented on a split-history-adjusted basis factoring in the complete ADPT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/27/2019 |
|
| End date: |
09/13/2024 |
|
| Start price/share: |
$40.30 |
|
| End price/share: |
$4.61 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-88.56% |
|
| Average Annual Total Return: |
-33.99% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,144.22 |
|
| Years: |
5.22 |
|
|
|
| Date |
Ratio |
| 04/06/1992 | 2 for 1
| | 01/31/1994 | 2 for 1
| | 11/18/1996 | 2 for 1
|
|
|
Free ADPT Email Alerts:
